Summary

Overview
The global atherosclerosis drugs market reached US$ 26.4 billion in 2023 and is expected to reach US$ 32.5 billion by 2031 growing with a CAGR of 2.6% during the forecast period 2024-2031.
Atherosclerosis is the buildup of fats, cholesterol, and other substances in and on the artery walls. This buildup is called plaque. The plaque can cause arteries to narrow, blocking blood flow. The plaque can also burst, leading to a blood clot. Although atherosclerosis is often considered a heart problem, it can affect arteries anywhere in the body. Atherosclerosis can be treated. Healthy lifestyle habits can help prevent atherosclerosis.
The market is driven by factors such as the increase in the prevalence of atherosclerosis & cardiovascular diseases and rising awareness about cardiovascular diseases. Drugs used in atherosclerosis are anti-platelet & anticoagulants, cholesterol-lowering medication, ACE inhibitors, fibric acid and omega-3 fatty acid derivatives, beta-blockers, and others.
Market Dynamics: Drivers
Increase in prevalence of cardiovascular & atherosclerosis diseases
The demand for the global atherosclerosis drugs market is driven by multiple factors. One of the primary factors is the increase in the prevalence of cardiovascular & atherosclerosis diseases. CVDs are a group of disorders of the heart and blood vessels and include atherosclerosis, coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70 years of age.
According to the MDPI research publication in October 2023, Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for 16.7 million deaths each year. The prevalence of atherosclerosis is increasing worldwide and more than 50% of people with circulatory disease die of it, mostly in modern societies.
Atherosclerosis is the main underlying cause of cardiovascular disease and is linked to an increased risk of heart attack and stroke, representing 85% of all deaths from CVD. As per the JAMA network in June 2022, the prevalence and burden of atherosclerosis in the general population have been reported in several studies, and the estimate of polyvascular atherosclerosis ranges from 3% to 42%. Similarly, AHA journals in September 2021, stated that the prevalence of atherosclerosis was 1.9 times higher in men than in women and increased sharply with age in both sexes.
Moreover, key players are more focused on the research & developments and the rising number of clinical trials in the CVD diseases would propel this market growth. For instance, in April 2024, New Amsterdam Pharma Company N.V. announced that it had met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial (“CVOT”) evaluating obicetrapib in adult patients with a history of atherosclerotic cardiovascular disease (“ASCVD”), who’s LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
Also, in August 2023, Merck announced the initiation of the company’s Phase 3 clinical program, CORAL reef, for MK-0616, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, being evaluated for the treatment of adults with hypercholesterolemia.
Restraints
Factors such as product recalls, high cost associated with the treatment, risk & side effects associated with the drugs, lack of awareness among individuals, stringent regulatory policies, lack of advanced healthcare infrastructure, low diagnosis rate, and availability of generic drugs, are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The global atherosclerosis drugs market is segmented based on drug type, route of administration, distribution channels, and region.
The cholesterol-lowering medication segment accounted for approximately 54.5% of the global atherosclerosis drugs market share
The cholesterol-lowering medication segment is expected to hold the largest market share over the forecast period. Cholesterol-lowering medications, particularly statins, are a mainstay of atherosclerosis treatment as they help reduce the buildup of plaque in arteries by lowering LDL ("bad") cholesterol levels.
Statins are commonly used to lower cholesterol, improve artery health, and prevent atherosclerosis. There are many other types of cholesterol-lowering drugs. They include niacin, fibrates, and bile acid sequestrants.
Moreover, key players in the industry more focus on research & development studies and getting positive results from the clinical trials in the CVD diseases that would propel this segment growth in this region. For instance, in February 2024, a research team based at the Centro National de Investigations Cardiovascular (CNIC) in Madrid and Aarhus University in Denmark identified an important mechanism that can result in the regression, or shrinkage, of atherosclerotic plaques. The study identifies cells derived from the smooth muscle cells in the arterial wall as a new target for future therapies.
According to Clinical Trials Arena in April 2024, Repatha (evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) for lowering cholesterol in patients. It is indicated to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease (CVD).
Similarly, in May 2024, LIB Therapeutics announces positive Lerodalcibep results from two phase 3 LIBerate studies at the 92nd European Atherosclerosis Society Congress. In addition, key player’s product approvals help to drive this segment's growth. For instance, in July 2023, - Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy. This patient population includes those who have comorbidities such as hypertension and diabetes and have not yet had a first cardiovascular event.
Geographical Analysis
North America accounted for approximately 41.2% of the global atherosclerosis drugs market share
North America region is expected to hold the largest market share over the forecast period. Heart disease has been the leading cause of death in the United States. According to the CDC's heart disease facts in May 2024, one person dies every 33 seconds from cardiovascular disease. About 695,000 people died from heart disease in 2021—that's 1 in every 5 deaths. Every year, about 805,000 people in the United States have a heart attack.
Obesity or overweight affects approximately 70% of American adults. Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke.
Moreover, a major number of key players' presence, well-advanced healthcare infrastructure, and product launches & approvals would propel this market growth in this region. For instance, in December 2021, Novartis announced the US Food and Drug Administration (FDA) approval of Leqvio (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.
Also, in February 2021, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first FDA-approved treatment that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism.
Market Segmentation
By Drug Type
• Anti-platelet & Anticoagulants
• Cholesterol Lowering Medication
• ACE Inhibitors
• Fibric Acid and Omega-3 Fatty Acid Derivatives
• Beta Blockers
• Others
By Route of Administration
• Oral
• Injectable
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the atherosclerosis drugs market include Pfizer Inc, AstraZeneca, Merck & Co., Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, GSK plc, Bayer AG, CSL and New Amsterdam Pharma Company N.V. among others.
Key Developments
 In March 2024, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight.
 In June 2023, AGEPHA Pharma USA, LLC, announced that, following a Priority Review, the U.S. Food and Drug Administration (FDA) has approved LODOCO as the first anti-inflammatory atheroprotective cardiovascular treatment demonstrated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.
Why Purchase the Report?
• To visualize the global atherosclerosis drugs market segmentation based on drug type, Route of Administration, distribution channels, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the antinauseant drugs market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global atherosclerosis drugs market report would provide approximately 62 tables, 59 figures, and 183 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channels
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases
4.1.1.2. Rising Awareness about Cardiovascular Diseases
4.1.2. Restraints
4.1.2.1. Product Recalls
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Drug Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Anti-platelet & Anticoagulants *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Cholesterol Lowering Medication
6.4. ACE Inhibitors
6.5. Fibric Acid and Omega-3 Fatty Acid Derivatives
6.6. Beta Blockers
6.7. Others
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration Market Attractiveness Index, By Route of Administration
7.2. Oral *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Injectable
8. By Distribution Channels
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
8.1.2. Market Attractiveness Index, By Distribution Channels
8.2. Hospital Pharmacies *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Pfizer Inc *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. AstraZeneca
11.3. Merck & Co., Inc.
11.4. Amgen Inc
11.5. Novartis AG
11.6. Eli Lilly and Company
11.7. GSK plc
11.8. Bayer AG
11.9. CSL
11.10. New Amsterdam Pharma Company N.V.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us